What happens next in GLP-1 — and when.

Get the briefing

What moved in the GLP‑1 field, in your inbox.

@glp1briefing

Indications › Obesity & overweight › orforglipron

orforglipron in obesity & overweight

orforglipron is approved in the US for obesity & overweight, and has 15 trials on file here in this condition. 14 of them are phase 3 or later. The next scheduled result is 2026-11.

15 registered trials study orforglipron (Foundayo) in obesity & overweight, 11 of them still active and 10 in phase 3. The next is due to report 2026-11.

Trials on file
15
Active
11
Active phase 3
10
Participants in active trials
9,542
Sponsors
2
Scheduled readouts
8

Scheduled to report

Dates are filed by the sponsor and move often. Each links to its own record and change history.

Est. completionTrialPhaseParticipants
2026-11A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT06649045 · Eli Lilly and Company
P3600
2027-02A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549 · Eli Lilly and Company
P3125
2027-08A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472 · Eli Lilly and Company
P3600
2027-08A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459 · Eli Lilly and Company
P3800
2027-08A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792 · Eli Lilly and Company
P31,400
2027-09A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435 · Eli Lilly and Company
P3487
2027-12A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT06672939 · Eli Lilly and Company
P3150
2028-03A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
NCT07790861 · Eli Lilly and Company
P3192

All trials on file

Every registered trial of orforglipron grouped under obesity & overweight, largest first. Grouping follows the registry’s own condition wording.

TrialStatusPhaseSponsor
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903
Active, not recruitingP3Eli Lilly and Company
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
NCT05803421
CompletedP3Eli Lilly and Company
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579
Not yet recruitingP3Eli Lilly and Company
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT05872620
CompletedP3Eli Lilly and Company
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792
Active, not recruitingP3Eli Lilly and Company
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459
Active, not recruitingP3Eli Lilly and Company
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472
Active, not recruitingP3Eli Lilly and Company
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT06649045
Active, not recruitingP3Eli Lilly and Company
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435
Active, not recruitingP3Eli Lilly and Company
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
NCT05051579
CompletedP2Eli Lilly and Company
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
NCT05931380
CompletedP3Eli Lilly and Company
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
NCT07790861
Not yet recruitingP3Eli Lilly and Company
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT06672939
RecruitingP3Eli Lilly and Company
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549
RecruitingP3Eli Lilly and Company
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation
NCT07729332
Not yet recruitingP4Massachusetts General Hospital

See the full record for orforglipron, or every molecule being studied in obesity & overweight. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.